Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, impairs an area of the eye (retina) used for reading, driving and many other ...

University of California San Diego researchers have identified a U-shaped association between high-density lipoprotein (HDL) ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration ... the sound of a voice to recognise who was there.

In the last 20 years, there have been rapid advances in the treatment options for myopic ... it is possible that patients with myopic macular degeneration complicated by CNV may benefit from ...

During my visit to CES 2025, I sought out a pair of special smart glasses that could give me hope for my son's future.

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

Currently, there is no cure for dry AMD, but two therapies appear effective ... With a better understanding of how age-related macular degeneration (AMD) occurs, researchers have been able to develop ...